Zurcher Kantonalbank Zurich Cantonalbank Purchases 21,205 Shares of DaVita Inc. (NYSE:DVA)

Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of DaVita Inc. (NYSE:DVA) by 28.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,657 shares of the company’s stock after acquiring an additional 21,205 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.10% of DaVita worth $10,021,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Everence Capital Management Inc. bought a new position in shares of DaVita in the fourth quarter worth $393,000. LifePlan Financial LLC purchased a new position in DaVita during the fourth quarter worth about $224,000. Sippican Capital Advisors increased its stake in DaVita by 19.0% in the 4th quarter. Sippican Capital Advisors now owns 15,618 shares of the company’s stock worth $1,636,000 after acquiring an additional 2,496 shares during the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of DaVita in the 4th quarter valued at about $346,000. Finally, Friedenthal Financial bought a new stake in shares of DaVita during the 4th quarter valued at about $713,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DaVita

In other DaVita news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock worth $16,551,071 in the last ninety days. 1.40% of the stock is owned by company insiders.

DaVita Trading Up 1.4 %

Shares of DVA opened at $127.82 on Friday. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $141.54. The firm has a market cap of $11.21 billion, a price-to-earnings ratio of 17.27, a PEG ratio of 1.12 and a beta of 1.04. The firm has a 50 day moving average price of $130.68 and a 200-day moving average price of $109.02. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. During the same period in the previous year, the firm posted $1.11 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, equities research analysts forecast that DaVita Inc. will post 9.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on DVA shares. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Barclays started coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target on the stock. UBS Group lifted their price objective on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Finally, Truist Financial raised their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.